Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11.
Michael D JainDavid Bernard MiklosCaron A JacobsonJohn M TimmermanJennifer SunJenny NaterXiang FangAnkit PatelMadison DavisDarren HeekeTan TrinhMike MattieFrank NeumannJenny J KimChristina ToSimone FilostoRan ReshefPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Utomilumab-mediated 4-1BB agonism combined with axi-cel therapy had a manageable safety profile. Dual 4-1BB and CD28 costimulation is a feasible therapeutic approach that may enhance CAR T-cell expansion in patients with LBCL.